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The glucocorticoid (GC)-induced antiinﬂammatory molecule annexin I is expressed in leukocytes and has antiinﬂammatory ef-
fects in animal models of arthritis, but the expression of annexin I in rheumatoid arthritis (RA) ﬁbroblast-like synoviocytes (FLS)
is unknown. We report the constitutive and dexamethasone (DEX)-inducible expression of annexin I in RA FLS. DEX increased
FLS annexin I protein translocation and mRNA expression. Interleukin (IL)-1β also induced annexin I translocation and mRNA
but also increased intracellular protein. DEX and IL-1 had additive eﬀects on annexin I mRNA, but DEX inhibited the inducing
eﬀe c to fI L - 1 β on cell surface annexin I. These results indicate that glucocorticoids and IL-1β upregulate the synthesis and translo-
cation of annexin I in RA FLS, but interdependent signalling pathways are involved.
Copyright © 2006 Eric F. Morand et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Glucocorticoids have been used in the treatment of human
rheumatoid arthritis (RA) for ﬁfty years see [1], but their
mechanisms of action remain incompletely understood
[2].
Glucocorticoids induce the synthesis and cell surface
translocation of annexin I (also known as lipocortin 1), a
37kD member of the annexin superfamily of calcium and
phospholipid binding proteins [3–5]. Antagonism of an-
nexin I worsens inﬂammation [6–10], suggesting annexin I
is a key participant in the antiinﬂammatory actions of gluco-
corticoids [2, 11].
AnnexinIhasbeendemonstratedinhumanbloodleuko-
cytesandRAtissue[12,13].Itexertsaconstitutiveinhibitory
inﬂuence, and mediates the inhibitor eﬀects of glucocor-
ticoids, in rodent models of RA [3, 9, 10, 14–16]. Regu-
lated expression of functionally active cell surface annexin
I binding sites has been reported in human RA ﬁbroblast-
like synoviocytes (FLS) [17, 18]. Despite this, the expres-
sion and regulation of annexin I in FLS has not been re-
ported. The present study was designed to examine the ex-
pression of annexin I in RA FLS, and to examine the regu-
lation of FLS annexin I by glucocorticoids and interleukin
(IL)-1β.
MATERIALS AND METHODS
Humansynovialﬁbroblastculture
All patients met American College of Rheumatology cri-
teria for the classiﬁcation of RA [19]. Cultured FLS were
grown from synovial specimens surgically excised from
knee, hip, and shoulder joints of patients with RA, as de-
scribed in [20]. Brieﬂy, synovial fragments (2–3mm) were
placed into 50mL (per 2g) of enzyme solution containing
1mg/mLDispase(0.5U/mg,BoehringerMannheim,Sydney,
Australia), 1mg/mL collagenase (type II, 1/mg; Sigma, St
Louis, Mich), and 1mg/mL DNase type I. (2,000units/mL;
Boehringer Mannheim) in Ca++ and Mg++ free Hanks’ bal-
anced salt solution (HBSS, ICN Laboratories, UK) stirred
for 1 hour at 37◦C. The digests were ﬁltered and washed.
C e l l sa tac o n c e n t r a t i o no f1 0 6–107 /mL were placed in
fresh RPMI/10% FCS and cultured at 37◦C, 5% CO2.A t
the third passage, cells were frozen in liquid nitrogen at
106 /mL in RPMI/20%FCS containing 10% dimethylsulfox-
ide (Ajax Chemicals, Sydney, Australia). Thawed cells were
used in experiments between passages 5–8. Cells were cul-
tured in RPMI/10% FCS and treated with dexamethasone
(DEX) (10−8–10−7 M) and/or IL-1β ( 1n g / m L )f o ru pt o2 4
hours.2 Mediators of Inﬂammation
AnalysisofcellsurfaceannexinI
CellsurfaceannexinIwasobtainedbywashingcellmonolay-
ers with PBS containing 10mM EDTA, as described in [14].
Brieﬂy, cell monolayers at 2×105 /mL were washed with PBS
and then with PBS containing 10mM EDTA for 3–5 minutes
at room temperature. Total protein was concentrated 10-fold
by centrifuge cryo-evaporation (Jouan, St Nazaire, France),
andresuspendedin20μlofPBSforsubsequentWesternblot-
ting with a speciﬁc antihuman annexin I monoclonal an-
tibody (mAb). Proteins were isolated by 12% Tris-HCL gel
and transferred onto nitrocellulose membrane. The nitrocel-
lulose was blocked for 1 hour in 5% skim milk in Tris buﬀer.
The membrane was subsequently incubated with 1μg/mL of
anti-annexin I mAb and HRP-conjugated rabbit antimouse
IgG (diluted 1 : 3000). The blot was ﬁnally developed using
a chemiluminescence system (ECL). The molecular masses
of the annexin I-positive immunoreactive bands were deter-
mined by comparison with the migration of molecular mass
standards. Recombinant annexin I was a generous gift from
Dr Y Giga-Hama, Osaka, Japan, and was assessed as a stan-
dard. Diﬀerences in blot density were conﬁrmed using NIH
Image (Bethesda, Md).
FlowcytometricdetectionofannexinI
Intracellular expression of human synovial ﬁbroblast an-
nexin I was detected using permeabilization ﬂow cytom-
etry using a Cytomation MoFlo ﬂow cytometer (Cytoma-
tion, Fort Collins, Colo, USA), as described in [21]. Brieﬂy,
cells were ﬁxed and permeabilized by suspension in 2%
paraformaldehyde and 0.2% saponin (Sigma)/PBS, then
incubated sequentially with annexin I (or control) mAb
and FITC-conjugated sheep antimouse IgG. Results are ex-
pressed as mean ﬂuorescence intensity (MFI) after subtrac-
tion of MFI obtained with isotype-control antibody labelled
cells.
RT-PCR
Reverse transcription of RNA was carried out as previously
described in [10]. The human annexin I primers used were
as follows: upstream primer (position 84–112 (28bp): GTA
TCA GAA TTC CTC AAG CAG GCC TGG T) and down-
stream primer (position 1082–1110 (28bp): TCC TCC ACA
AAG AGC CAC CAG GAT TTT C). Primers for the control
gene GAPDH were: 5  CGT CTT CAC CAC CAT GGA GA
3  (forward); 5  CGG CCA TCA CGC CAC AGT TT 3  (re-
verse), yielding a PCR product of 300bp. cDNA was am-
pliﬁed for 30 cycles using a DNA thermal cycler (Hybaid,
Omnigene). Following PCR, the ampliﬁed products were
analyzed on a 1.6% agarose gel containing ethidium bro-
mide, with a size marker (123bp ladder, Gibco BRL), and
gel loading was normalized to GAPDH products. Diﬀer-
ences in intensity of staining between treatment and control-
derivedRNAwereconﬁrmedwithanimageanalyzingsystem
(Kodak Digital EDAS).
Competitive RT-PCR was performed as described in
[10]. Brieﬂy, PCR MIMICs were generated by two successive
PCR ampliﬁcations according to the PCR MIMIC construc-
tion kit (Clontech Laboratories, Inc, Palo Alto, Calif). Four-
fold dilutions of each PCR MIMIC between 10−1–10−2 at-
tomole/mL were added to PCR ampliﬁcation reactions con-
taining a constant amount of the sample cDNA. The PCR
ampliﬁcation was performed in one cycle for 5 minutes at
95◦C, and in 26 cycles for denaturing at 94◦C for 45 seconds,
annealing at 55◦C for 45 seconds and extending at 72◦Cf o r
90 seconds. To determine the amount of the target mRNA,
PCR products were separated on a 1.6% agarose gel, and the
intensity of staining was analyzed using computerized scan-
ner and image analysis software (NIH Image). The concen-
tration of the target mRNA was derived from the zero inter-
sect of the log ratio of target to mimic PCR products [10].
Statisticalanalysis
The data are presented as mean ± SEM and analyzed by
Mann-Whitney U test or Student t test. Values of P<. 05
were regarded as statistically signiﬁcant. Group sizes referred
to in the text refer to numbers of experiments; in each case
each experiment was performed with cells from a diﬀerent
donor.
RESULTS
EffectofDEXonFLSannexinI
To investigate the expression and regulation of annexin I in
FLS, annexin I mRNA was measured using competitive RT-
PCR. Annexin I mRNA was constitutively expressed in RA
FLS (Figure 1). DEX induced increased annexin I mRNA in
RA synovial ﬁbroblasts at 24 hours (Figure 1). In contrast,
intracellular annexin I was inhibited by DEX, exhibiting a
trend towards a signiﬁcant reduction after 3 hours exposure
to DEX (MFI (×103):1 .7 ± 0.1c f1 .5 ± 0.2,P = .057)
and a signiﬁcant reduction at 24 hours (MFI: 1.8 ± 0.3c f
1.4 ± 0.3,n = 6,P<. 01) (Figure 2). In contrast to the re-
duction in intracellular annexin I protein, DEX treatment
increased cell surface annexin I at 3 hours and 24 hours
(Figure 3). These data suggest that DEX induces the translo-
cation of intracellular annexin I to the cell surface, followed
by increased expression of annexin I mRNA. A smaller 33kD
fragment, previously shown to be a glucocorticoid-inducible
fragment of annexin I [14], was also shown to be increased
by DEX.
Effectofinterleukin-1ßonFLSannexinI
Treatment with IL-1β also increased FLS annexin I mRNA
(Figure 4). IL-1β treatment also increased RA FLS cell sur-
face annexin I (Figure 5). In contrast to the eﬀect of DEX,
however, IL-1β signiﬁcantly increased intracellular annexin I
protein as well as cell surface annexin I, in comparison with
control (Figure 6)( P = .007).Eric F. Morand et al 3
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Figure 1: DEX eﬀects on RA synovial ﬁbroblast annexin I mRNA.
Panel (a): RNA extracted from human RA FLS was subjected to
competitive RT-PCR with (lanes 2–6 and 8–12) or without (lanes
1 and 7) mimic. Lanes 1–6: control; lanes 7–12: DEX 10−7 Mf o r2 4
hours. Annexin I mRNA content was greater in DEX-treated than
vehicle-treated cells. Representative of n = 4 separate experiments
from 4 separate RA donors. Panel (b): the log of the ratios of the
annexin I and mimic PCR product band intensities were graphed
as a function of the log of the amount of mimic added to the re-
action. Increased annexin I mRNA is seen in DEX-treated RA syn-
ovial ﬁbroblasts. Representative of n = 4 separate experiments from
4 separate RA donors.
InteractionofDEXandIL-1βonFLSannexinI
To assess whether the eﬀects of glucocorticoid and IL-1β
on FLS annexin I synthesis were additive, cells were co-
tr e a t e dwi t hD E Xa n dI L - 1 β. Annexin I mRNA was markedly
and dose-dependently increased by the combination of DEX
and IL-1βs, with signiﬁcantly greater annexin I expression
observed when compared to either IL-1β or DEX alone
(Figure 4). Surprisingly, the addition of DEX to IL-1β led
to inhibition of cell surface annexin I compared to either
alone or untreated cells (Figure 5). These results suggest that
the eﬀects of IL-1 on cell surface annexin I are inhibited by
DEX, despite DEX being an inducer of cell surface annexin
I in its own right. The addition of DEX to IL-1β also led
to reduced intracellular annexin I protein compared to IL-
1β alone (P<. 05) (Figure 6), suggesting that increase in
annexin I mRNA with combination of DEX and IL-1 was
32 4
(h)
1000
1500
2000
2500
M
F
I
∗
Vehicle
DEX
Figure 2: DEX eﬀects on RA synovial ﬁbroblast intracellular an-
nexin I. Annexin I protein was detected in cultured RA FLS by per-
meabilization ﬂow cytometry and displayed as mean ± SEM mean
ﬂuorescence intensity (MFI). Compared to control (open bars),
cells treated with DEX 10−7 M (ﬁlled bars) exhibited reduced in-
tracellular annexin I at 3 hours and 24 hours, respectively (n = 6).
∗P<. 05.
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Figure 3:DEXeﬀectsonRAsynovialﬁbroblastcellsurfaceannexin
I. RA FLS were exposed to DEX 10−7 M for 3 hours and 24 hours,
respectively. Cell surface annexin I was detected by Western blot-
ting. Lanes 1 and 2 show 3-hour control, and DEX-treated cell sur-
face eluates, lanes 3 and 4 show 24-hour control, and DEX-treated
cell surface eluates. A 37kD band representing full-length annexin I
was increased at 3 hours and increased further at 24 hours in DEX.
A smaller 33kD fragment of annexin I was also increased by DEX.
Data presented are from one experiment representative of n = 4.
inhibited post-transcriptionally leading to increase in an-
nexin I protein.
DISCUSSION
The very broad range of antiinﬂammatory eﬀects of an-
nexin I [7, 14, 22–24] suggests its potential as an endoge-
nous and glucocorticoids induced antiinﬂammatory regu-
lator in a disease such as RA. Antagonism of annexin I4 Mediators of Inﬂammation
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Figure 4: IL-1β and DEX eﬀects on RA synovial ﬁbroblast annexin
I mRNA. RA FLS were exposed to IL-1β 1ng/mL and DEX 10−7–
10−8 M for 24 hours and annexin I mRNA measured by semiquan-
titative RT-PCR. Upper bands: annexin I, lower bands: GAPDH.
Lane 1: control; lane 2: DEX 10−7 M; lane 3: DEX 10−8 M; lane 4:
IL-1β 1ng/mL;lane5:IL-1β plus DEX 10−7 M; lane 6: IL-1β plus
DEX 10−8 M. DEX and IL-1β both induced annexin I mRNA. Co-
treatment with DEX and IL-1β had additive eﬀects on annexin I
mRNA. Data presented are from one experiment representative of
n = 4.
12 3 4
Figure 5: IL-1β and DEX eﬀects on RA synovial ﬁbroblast cell sur-
face annexin I. RA FLS were exposed to IL-1β 1ng/mL and DEX
10−7–10−8 M for 24 hours. Cell surface annexin I was detected by
Western blotting. Lane 1 and 2 show control, and IL-1β-treated
cells, lane 3 and 4 show IL-1β +D E X( 1 0 −7 and 10−8 M)-treated
cells. Cell surface annexin I was increased by IL-1β. Cotreatment
withDEXandIL-1β inhibitedcellsurfaceannexinI.Datapresented
are from one experiment representative of n = 3.
exacerbates rat adjuvant and carrageenan-induced arthritis
[9, 10], and in adjuvant arthritis, this is associated with in-
creased synovial prostaglandin E2 and TNF-α [10]. More-
over, in both models, antagonism of annexin I prevents the
eﬀects of exogenous glucocorticoids. Recent studies demon-
stratedthatdisruptionoftheAnx-1geneinmiceexacerbated
arthritis severity and proinﬂammatory cytokine expression
in antigen-induced arthritis [16]. The absence of Anx-1 was
also associated with insensitivity to the antiinﬂammatory ef-
fects of dexamethasone, indicating a major role for Anx-1 in
the pathopharmacology of inﬂammation [16]. Annexin I has
been demonstrated in human peripheral blood leukocytes
andinRAsynovium[12,13],andannexinIcellsurfacebind-
ing sites have been demonstrated in RA FLS [17, 18]. Syn-
ovial ﬁbroblasts are important contributors to the pathology
ofRA,buttheregulationofannexinIinhumansynovialcells
by pro- and antiinﬂammatory mediators has not been previ-
ously reported.
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Figure 6: IL-1β and DEX eﬀects on RA synovial ﬁbroblast intracel-
lularannexinI.RAFLSwereculturedfor24hourswithinterleukin-
1β (IL-1, 1ng/mL), and/or DEX (DEX, 10−8 M). Annexin I pro-
tein was detected by permeabilization ﬂow cytometry and displayed
as mean ± SEM mean ﬂuorescence intensity (MFI). IL-1β signiﬁ-
cantly increased intracellular annexin I (∗P<. 01). The addition of
DEX 10−8 Mp r e v e n t e dt h ee ﬀect of IL-1β on intracellular annexin
I( †P<. 05) (n = 6).
In the current study, we demonstrate that RA FLS con-
stitutively express annexin I. DEX induced annexin I mRNA,
associated with a concomitant reduction in intracellular an-
nexin I, and an increase in cell surface annexin I. The in-
creased annexin I mRNA in cells treated with DEX suggests
that the reduction in intracellular annexin I protein is not
the result of reduced synthesis but rather of increased export
to the cell surface. These data suggest that DEX ﬁrst induces
the translocation of pre-existing annexin I to the cell surface,
followed by reconstitution via new mRNA expression.
The current results also demonstrate that IL-1β increases
annexin I transcription, synthesis, and cell surface translo-
cation in FLS. IL-1β induces c-jun/fos AP-1 subunit activa-
tion in RA FLS [25], and as the annexin I promoter region
contains an AP-1 site [26]t h i si sl i k e l yt ob ei n v o l v e di n
the response to IL-1β. Induction of antiinﬂammatory pro-
teins by pro-inﬂammatory stimuli such as IL-1 is not sur-
prising, as many molecules such as IL-10 are inducible by
pro-inﬂammatory cytokines and participate in the regula-
tory control of inﬂammation. Given the positive eﬀects of
both DEX and IL-1β, we anticipated an interaction between
these stimuli on FLS annexin I. The combination of DEX
and IL-1β additively induced annexin I mRNA consistent
with additive eﬀects on separate transcription factors. Sur-
prisingly, however, the addition of DEX to IL-1 was asso-
ciated with reductions in both intracellular and cell surface
protein. Of note, IL-1β treatment did not induce the cell
surface expression of the smaller 33kD annexin I fragment
which was observed with DEX treatment. The discrepant ef-
fectsofDEXandIL-1β onFLSintracellularannexinIprotein
suggests that the synthesis and cell surface translocation ofEric F. Morand et al 5
annexinIarediﬀerentlyregulatedbythesetwostimuli.These
ﬁndings are consistent with the existence of diﬀerential post-
transcriptionaleﬀectsofDEXandIL-1βonannexinIsynthe-
sis. On the basis that the antiinﬂammatory eﬀects of annexin
Id e p e n du p o nc e l ls u r f a c et r a n s l o c a t i o n[ 7], the prevention
by IL-1β of DEX-induced annexin I surface translocation is
consistent with cytokine-dependent limitation of annexin I
in the setting of inﬂammation. In RA synovium, IL-1β is
chronically overproduced, and thus the eﬀect of physiolog-
ical and pharmacological glucocorticoids on annexin I may
be chronically and speciﬁcally inhibited. No data exists on
the eﬀects of speciﬁc IL-1 antagonism, for example, using re-
combinant IL-1RA products such as anakinra, on annexin I
expression in human RA.
Although GC are eﬀective agents in the treatment of
RA, a proportion of patients with RA and other inﬂam-
matory diseases are resistant to their therapeutic eﬀects.
GC sensitivity has been reported to be associated with re-
duced GC receptor nuclear translocation [27], increased ex-
pression of GC receptor β [28]—migration inhibitory fac-
tor (Aeberli et al, FEBS Letters in press). Annexin I re-
sponses to GC may also potentially be associated with GC
resistance. Certainly, leukocyte intracellular annexin I pro-
tein responses to glucocorticoids are impaired in RA pa-
tients [29], leukocytes and synovial ﬁbroblast cell surface
annexin I binding sites are reduced in RA patients [17,
18, 30], and sensitivity to GC in arthritic mice is impaired
in the absence of annexin I [16]. Annexin I expression
is possibly an index for recognition of GC resistance. Di-
rect links between annexin I and the complicated molecular
mechanisms of GC resistance remain to be further investi-
gated.
In conclusion, glucocorticoids and IL-1β each increases
the expression and cell surface translocation of annexin I in
human RA FLS. Discrepant eﬀects of combined DEX and IL-
1β suggest post-transcriptional interactions. Further studies
are required to deﬁne the mechanisms of cell surface translo-
cation of annexin I, the signaling pathways involved in glu-
cocorticoid and cytokine regulation of synoviocyte annexin
I, and the mechanism(s) of antiinﬂammatory action of an-
nexin I.
CONCLUSION
Annexin I is an important antiinﬂammatory protein, shown
here to be constitutively expressed in human RA synovio-
cytes. The upregulation of synoviocyte annexin I by DEX
supports the hypothesis that annexin I is involved in the
physiological and pharmacological eﬀects of glucocorticoids
in RA. The discrepant eﬀects of IL-1β in the presence and
absence of DEX suggest diﬀerential regulation of annexin I
transcription, synthesis, and translocation.
REFERENCES
[1] Laan RF, Jansen TL, van Riel PL. Glucocorticosteroids in the
management of rheumatoid arthritis. Rheumatology (Oxford).
1999;38(1):6–12.
[2] Barnes PJ. Anti-inﬂammatory actions of glucocorticoids:
molecular mechanisms. Clinical Science (London). 1998;94(6):
557–572.
[3] Yang YH, Hutchinson P, Leech M, Morand EF. Exacerbation
of adjuvant arthritis by adrenalectomy is associated with re-
duced leukocyte lipocortin 1. The Journal of Rheumatology.
1997;24(9):1758–1764.
[4] Philip JG, Flower RJ, Buckingham JC. Glucocorticoids modu-
late the cellular disposition of lipocortin 1 in the rat brain in
vivo and in vitro. Neuroreport. 1997;8(8):1871–1876.
[5] Comera C, Russo-Marie F. Glucocorticoid-induced annexin
1 secretion by monocytes and peritoneal leukocytes. British
Journal of Pharmacology. 1995;115(6):1043–1047.
[6] Perretti M, Flower RJ. Modulation of IL-1-induced neutrophil
migration by dexamethasone and lipocortin 1. Journal of Im-
munology. 1993;150(3):992–999.
[7] Perretti M, Croxtall JD, Wheller SK, Goulding NJ, Hannon R,
Flower RJ. Mobilizing lipocortin 1 in adherent human leuko-
cytes downregulates their transmigration. Nature Medicine.
1996;2(11):1259–1262.
[8] Perretti M, Ahluwalia A, Harris JG, Harris HJ, Wheller SK,
Flower RJ. Acute inﬂammatory response in the mouse: exacer-
bation by immunoneutralization of lipocortin 1. British Jour-
nal of Pharmacology. 1996;117(6):1145–1154.
[9] Yang YH, Leech M, Hutchinson P, Holdsworth SR, Morand
EF. Antiinﬂammatory eﬀect of lipocortin 1 in experimental
arthritis. Inﬂammation. 1997;21(6):583–596.
[10] Yang YH, Hutchinson P, Morand EF. Inhibitory eﬀe c to fa n -
nexin I on synovial inﬂammation in rat adjuvant arthritis.
Arthritis and Rheumatism. 1999;42(7):1538–1544.
[11] Solito E, Romero IA, Marullo S, Russo-Marie F, Weksler BB.
Annexin 1 binds to U937 monocytic cells and inhibits their
adhesion to microvascular endothelium: involvement of the
alpha 4 beta 1 integrin. Journal of Immunology. 2000;165(3):
1573–1581.
[12] Morand EF, Hutchinson P, Hargreaves A, Goulding NJ, Boyce
NW, Holdsworth SR. Detection of intracellular lipocortin 1
in human leukocyte subsets. Clinical Immunology and Im-
munopathology. 1995;76(2):195–202.
[13] Goulding NJ, Dixey J, Morand EF, et al. Diﬀerential distribu-
tion of annexins-I, -II, -IV, and -VI in synovium. Annals of the
Rheumatic Diseases. 1995;54(10):841–845.
[14] Yang YH, Hutchinson P, Santos LL, Morand EF. Glucocorti-
coid inhibition of adjuvant arthritis synovial macrophage ni-
tric oxide production: role of lipocortin 1. Clinical and Exper-
imental Immunology. 1998;111(1):117–122.
[15] Yang YH, Hall P, Milenkovski G, et al. Reduction in arthri-
tis severity and modulation of immune function in tissue fac-
tor cytoplasmic domain mutant mice. The American Journal of
Pathology. 2004;164(1):109–117.
[16] Yang YH, Morand EF, Getting SJ, et al. Modulation of in-
ﬂammation and response to dexamethasone by Annexin 1 in
antigen-induced arthritis. Arthritis and Rheumatism. 2004;50
(3):976–984.
[17] Sampey AV, Hutchinson P, Morand EF. Annexin I and dexam-
ethasone eﬀects on phospholipase and cyclooxygenase activity
in human synoviocytes. Mediators of Inﬂammation. 2000;9(3-
4):125–132.
[18] Sampey AV, Hutchinson P, Morand EF. Annexin I surface
binding sites and their regulation on human ﬁbroblast-like
synoviocytes. Arthritis and Rheumatism. 2000;43(11):2537–
2542.
[19] Arnett FC, Edworthy SM, Bloch DA, et al. The Ameri-
can Rheumatism Association 1987 revised criteria for the6 Mediators of Inﬂammation
classiﬁcation of rheumatoid arthritis. Arthritis and Rheuma-
tism. 1988;31(3):315–324.
[20] Leech M, Metz C, Hall P, et al. Macrophage migration in-
hibitoryfactorinrheumatoidarthritis:evidenceofproinﬂam-
matory function and regulation by glucocorticoids. Arthritis
and Rheumatism. 1999;42(8):1601–1608.
[21] Morand EF, Hutchinson P, Boyce NW, Goulding NJ,
Holdsworth SR. Expression of intracellular lipocortin 1 in hu-
man peripheral blood leukocyte subsets. AustNZJMed. 1995;
25:405.
[22] CirinoG,FlowerRJ.Humanrecombinantlipocortin1inhibits
prostacyclin production by human umbilical artery in vitro.
Prostaglandins. 1987;34(1):59–62.
[23] Gold R, Pepinsky RB, Zettl UK, Toyka KV, Hartung HP.
Lipocortin-1 (annexin-1) suppresses activation of autoim-
muneTcelllinesintheLewisrat.JournalofNeuroimmunology.
1996;69(1-2):157–164.
[24] Kim KM, Kim DK, Park YM, Kim CK, Na DS. Annexin-I in-
hibits phospholipase A2 by speciﬁc interaction, not by sub-
strate depletion. FEBS Letters. 1994;343(3):251–255.
[25] Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-
kappaB and mitogen-activated protein kinase/AP-1 pathways
at the collagenase-1 promoter: divergence of IL-1 and TNF-
dependent signal transduction in rabbit primary synovial ﬁ-
broblasts. Cytokine. 2000;12(10):1469–1479.
[26] Browning JL, Ward MP, Wallner BP, Pepinsky RB. Studies on
the structural properties of lipocortin-1 and the regulation of
its synthesis by steroids. Progress in Clinical and Biological Re-
search. 1990;349:27–45.
[27] Bloom JW. Mitogen-activated protein kinase pathways: thera-
peutic targets in steroid resistance? The Journal of Allergy and
Clinical Immunology. 2004;114(5):1055–1058.
[28] Derijk RH, Schaaf MJ, Turner G, et al. A human glucocor-
ticoid receptor gene variant that increases the stability of
the glucocorticoid receptor beta-isoform mRNA is associ-
ated with rheumatoid arthritis. The Journal of Rheumatology.
2001;28(11):2383–2388.
[29] Morand EF, Jeﬀeriss CM, Dixey J, Mitra D, Goulding NJ.
Impaired glucocorticoid induction of mononuclear leukocyte
lipocortin-1 in rheumatoid arthritis. Arthritis and Rheuma-
tism. 1994;37(2):207–211.
[30] Goulding NJ, Jeﬀeriss CM, Pan L, Rigby WF, Guyre PM. Spe-
ciﬁc binding of lipocortin-1 (annexin I) to monocytes and
neutrophils is decreased in rheumatoid arthritis. Arthritis and
Rheumatism. 1992;35(11):1395–1397.